- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Laurence Klotz discusses the challenges and pitfalls in active surveillance for prostate cancer. He highlights the dual goals of avoiding unnecessary treatment while identifying patients who would benefit from intervention. Dr. Klotz addresses issues leading to overtreatment, such as overgrading,...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Declan Murphy discusses the impact of widespread MRI use on Grade Group 1 prostate cancer diagnosis in Australia. He highlights that since the introduction of fully funded MRI access in 2018, the proportion of newly diagnosed Grade Group 1 cancers has dropped from 40% to less than 20%. Dr. Murphy...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Caroline Moore discusses the differences between active surveillance and watchful waiting in prostate cancer management. Dr. Moore highlights that MRI-led pathways have reduced the diagnosis of low-risk prostate cancers in England, similar to Australia's experience. She concludes by questioning w...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Andrew Vickers addresses concerns about underdiagnosing low-volume Grade Group 2 prostate cancer when considering the reclassification of Grade Group 1. He argues that the benefits of reducing overdiagnosis and overtreatment outweigh speculative risks. Dr. Vickers concludes by emphasizing the nee...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Ruth Etzioni discusses the potential role of modeling in evaluating the implications of relabeling Grade Group 1 prostate cancer. She emphasizes that while models cannot yet provide definitive answers, they can help compare different scenarios. Dr. Etzioni concludes that properly specifying these...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Andrew Vickers addresses concerns about underdiagnosing low-volume Grade Group 2 prostate cancer when considering reclassification of Grade Group 1. He argues that many objections to redesignation are speculative and fail to consider the current problems of overdiagnosis, overtreatment, and patie...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the complexities of prostate cancer classification and the potential reclassification of Grade Group 1 tumors. They explore the importance of cribriform patterns in Pattern 4 cancers and the consistency of pathological identification. The conversation touches on historical changes...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, CJ Stimpson discusses the potential impact of changing nomenclature on alternative payment models (APMs) for prostate cancer. He asserts that such changes would not cause significant problems in developing or executing APMs, as these models are rare for prostate cancer and must already adapt to f...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Derya Tilki challenges the notion that Europe doesn't have issues with active surveillance uptake for prostate cancer, highlighting the heterogeneity across European countries. Dr. Tilki specifically mentions Germany, where only about 30% of eligible patients opt for active surveillance, partly d...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Mohamed Jalloh discusses two significant studies on prostate cancer in Africa. The first, a 2013 evaluation, examines pathology outcomes across six African countries, revealing varying proportions of Gleason 6 cases. The second, a more recent prospective study in West and Southern Africa, analyze...
|
